Patent intelligence · US
US 10080739
Aryl imidazoles and their use as anti-cancer agents
Aryl imidazoles and their use as anti-cancer agents
Patent details — US 10080739
- Jurisdiction
- US
- Status
- granted
- Grant date
- Sep 25, 2018
- Expiration
- Sep 20, 2038
- Applicant
- APTOSE BIOSCIENCES INC.
- Claims
- 22
- CPC classes
- A61K, A61K31/4178, A61K31/4184, A61K31/4188
Quick answer
US 10080739 (Aryl imidazoles and their use as anti-cancer agents) is held by APTOSE BIOSCIENCES INC.. Status: granted. Granted Sep 25, 2018. Expires Sep 20, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- APTOSE BIOSCIENCES INC.
- Grant date
- Expiration
- Claims
- 22
- CPC classes
- A61K, A61K31/4178, A61K31/4184, A61K31/4188, A61K31/4745, A61P
More from APTOSE BIOSCIENCES INC.
Related pharmaceutical patents in our USPTO index.
-
US 11279703
Fused pyrimidine compounds as BRD4 and JAK2 dual inhibitors and methods for use thereof
granted -
US 11149047
Aryl imidazoles for treatment of cancer
granted -
US 11104957
Compositions and methods for treating cancers
granted -
US 9567643
Compositions and methods for treating cancers
granted -
US 8987305
2,4,5-trisubstituted imidazoles and their use as anti-microbial agents
granted -
US 8969372
Aryl imidazoles and their use as anti-cancer agents
granted
Frequently asked questions
What is US patent 10080739?
US 10080739 (Aryl imidazoles and their use as anti-cancer agents) is held by APTOSE BIOSCIENCES INC.. Status: granted. Granted Sep 25, 2018. Expires Sep 20, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10080739?
APTOSE BIOSCIENCES INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 7 pharmaceutical patents for this assignee.
When does US 10080739 expire?
Our index shows an expiration date of Sep 20, 2038 (12 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.